AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's

According to STAT, Pathos announced on Friday that it is raising $237 million in a Series E funding round led by Bristol Myers Squibb. The round values Pathos at about $3 billion.

Pathos has worked in cancer drug development. It is now expanding into neurological conditions. STAT reports that the move relies on new datasets from Tempus AI and on a partnership with Bristol Myers Squibb that will first focus on Alzheimer's treatments.

The reason for the bet is a familiar problem. STAT notes that most drugs that enter clinical trials never reach patients. Pathos' pitch, according to STAT, is that AI can improve those odds.

Its system is called Foundry. It runs thousands of software agents, which are programs that each work on a piece of the analysis. They calculate the probability that a drug the company is developing will succeed. STAT says they look at clinical data, genomics, data from biological specimens and competition from other developers.

That analysis guides three kinds of choices, according to STAT: which drugs to pursue, which groups of people to test them in, and how to design the clinical trials.

For people interested in healthspan, the relevance is indirect. Better choices about drugs, patients and trial design could, in principle, make dementia trials more likely to give clear answers. That is an interpretation of the company's pitch, not a finding.

It is also important to be clear about what this news is. It is a funding and partnership announcement. The portion of the STAT story available to us reports no patient results, no named Alzheimer's drug and no trial data. Whether Foundry's probability estimates are accurate, or whether they improve on how drugs are chosen today, is not shown in that text.

Much of the STAT article is behind a subscription wall, so details such as the specific drug candidates and timelines are not covered here.

What to watch next

Whether the Bristol Myers Squibb partnership names Alzheimer's drug candidates and begins clinical trials, and whether any results from those trials are published.

Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70 Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory